NCT05236621

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

A Multicenter, Open-Label, Single-Arm Clinical Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of permadomide capsules developed by Qilu Pharmaceutical Co., LTD.

Conditions

• Multiple Myeloma
• Recurrent or Refractory

Interventions

Type	Name	Description
DRUG	Pomalidomide	4 mg pomalidomide capsules administered orally
DRUG	Dexamethasone	40 mg dexamethasone tablets administered orally

Timeline

• Start date: 2021-01-04
• Primary completion: 2022-06-01
• Completion: 2023-12-01
• First posted: 2022-02-11
• Last updated: 2022-02-11

Locations

23 sites across 1 country: China